Teladoc Health (NYSE:TDOC) Posts Earnings Results, Beats Estimates By $0.03 EPS

Teladoc Health (NYSE:TDOC) issued its earnings results on Wednesday. The health services provider reported ($0.21) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.03, Zacks reports. Teladoc Health had a negative net margin of 7.13% and a negative return on equity of 12.02%. The business had revenue of $606.93 million for the quarter, compared to analyst estimates of $615.44 million. During the same period in the previous year, the business earned ($0.19) EPS. The firm’s revenue was down 4.0% on a year-over-year basis. Teladoc Health updated its Q3 2026 guidance to -0.300–0.200 EPS and its FY 2026 guidance to -1.000–0.750 EPS.

Here are the key takeaways from Teladoc Health’s conference call:

• BetterHelp’s outlook was reduced: 2026 segment revenue is now expected at $770 million–$830 million as U.S. cash-pay revenue declines faster than anticipated, driven by a quicker shift toward insurance, lower advertising, and provider-capacity constraints.
• BetterHelp’s insurance business is gaining traction, with more than 8,000 credentialed providers, over $150 million of contracted in-network lives, and more than 20,000 weekly insurance sessions representing an annualized revenue run rate above $110 million.
• Management accelerated BetterHelp’s insurance rollout to all 50 states and Washington, D.C., while redirecting marketing and operating resources toward U.S. insurance; however, executives said the timing of closing capacity gaps remains uncertain and expect continued cash-pay pressure.
• Integrated Care delivered solid results: revenue rose 0.7% to $394 million, adjusted EBITDA increased 13.6% to $65 million, chronic-care enrollment grew 14% year over year to 1.27 million, and full-year EBITDA margin guidance was raised.
• Teladoc launched Teladoc One, a unified AI-enabled care model spanning clinicians, specialists, therapists, coaches, and dieticians, with broad availability planned for January 2027 beginning in cardiometabolic care.

Teladoc Health Price Performance

Teladoc Health stock traded up $0.09 during trading hours on Friday, hitting $6.67. 1,691,266 shares of the stock were exchanged, compared to its average volume of 5,509,249. The company has a debt-to-equity ratio of 0.75, a quick ratio of 2.72 and a current ratio of 2.80. The stock has a market capitalization of $1.20 billion, a P/E ratio of -6.75 and a beta of 2.10. Teladoc Health has a 12 month low of $4.40 and a 12 month high of $9.89. The business’s 50-day moving average is $8.21 and its two-hundred day moving average is $6.54.

Insiders Place Their Bets

In other news, insider Carlos Nueno sold 6,196 shares of the stock in a transaction on Tuesday, June 2nd. The stock was sold at an average price of $7.63, for a total transaction of $47,275.48. Following the sale, the insider owned 57,671 shares in the company, valued at approximately $440,029.73. This represents a 9.70% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Fernando M. Rodrigues sold 5,677 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $7.63, for a total value of $43,315.51. Following the completion of the sale, the insider owned 9,572 shares of the company’s stock, valued at approximately $73,034.36. This trade represents a 37.23% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders have sold 39,195 shares of company stock worth $299,058. 0.70% of the stock is owned by company insiders.

Hedge Funds Weigh In On Teladoc Health

A number of large investors have recently modified their holdings of the stock. IFP Advisors Inc boosted its holdings in Teladoc Health by 412.1% in the third quarter. IFP Advisors Inc now owns 3,989 shares of the health services provider’s stock valued at $31,000 after acquiring an additional 3,210 shares during the last quarter. PNC Financial Services Group Inc. raised its holdings in Teladoc Health by 177.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,391 shares of the health services provider’s stock worth $31,000 after purchasing an additional 2,810 shares during the last quarter. Van ECK Associates Corp lifted its position in Teladoc Health by 101.4% during the 4th quarter. Van ECK Associates Corp now owns 9,150 shares of the health services provider’s stock valued at $64,000 after purchasing an additional 4,607 shares during the period. Johnson Financial Group Inc. lifted its position in Teladoc Health by 41,045.8% during the 3rd quarter. Johnson Financial Group Inc. now owns 9,875 shares of the health services provider’s stock valued at $76,000 after purchasing an additional 9,851 shares during the period. Finally, Envestnet Asset Management Inc. bought a new position in shares of Teladoc Health in the 2nd quarter valued at about $89,000. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Teladoc Health News Roundup

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Teladoc reported a second-quarter loss of $0.21 per share, better than the consensus estimate of a $0.24 loss. Strength in the Integrated Care segment and international business helped offset weakness elsewhere. Teladoc Health Q2 Earnings Beat Estimates on Integrated Care Strength
• Positive Sentiment: Management’s cost controls continued to support profitability trends: the company generated $64.7 million in operating cash flow, while the first-half net loss narrowed even as sales declined. Do Teladoc’s Weaker Q2 Results Signal a Turning Point in Its Profit Path?
• Neutral Sentiment: Canaccord Genuity maintained a “buy” rating but lowered its price target from $11 to $10, implying substantial potential upside if Teladoc stabilizes growth. Unusually high call-option activity also suggested that some traders were positioning for a rebound, though options activity is not a fundamental signal.
• Negative Sentiment: Second-quarter revenue fell 4% year over year to $606.9 million, below analysts’ roughly $615.4 million forecast. The company also posted a $38.9 million net loss, compared with a $0.19-per-share loss in the year-earlier quarter. Teladoc Stock Plummets on Revenue Miss, Lowered Outlook
• Negative Sentiment: BetterHelp remains the main concern. Shifts in demand reduced cash-pay revenue at the mental-health unit, prompting Teladoc to cut its full-year revenue outlook to approximately $2.4 billion, below the $2.5 billion consensus estimate. Teladoc tumbles on revenue forecast cut as BetterHelp demand shifts hurt
• Negative Sentiment: Third-quarter revenue guidance of $569 million to $609 million was well below Wall Street’s $629.1 million expectation, while projected EPS of a $0.20 to $0.30 loss was weaker than the anticipated $0.17 loss. The cautious near-term outlook outweighed the earnings beat and drove the negative reaction. Why Teladoc Health Stock Is Dropping Thursday Following Soft Q3 Outlook

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on TDOC shares. Canaccord Genuity Group decreased their price objective on Teladoc Health from $11.00 to $10.00 and set a “buy” rating on the stock in a report on Thursday. Bank of America increased their target price on Teladoc Health from $9.00 to $10.50 and gave the stock a “buy” rating in a report on Tuesday, July 7th. Citigroup raised their target price on Teladoc Health from $6.00 to $7.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 5th. Finally, Weiss Ratings upgraded Teladoc Health from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 22nd. Five equities research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $7.50.

Teladoc Health Company Profile

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.